Regulatory Approval - Lilly's Alzheimer's disease drug Kisunla receives backing from EU regulators for use in a specific patient group [1]

Funding & Investment - Illimis Therapeutics secured 58 billion won (approximately $42 million) in funding [1] - The funding aims to support research into Alzheimer's disease treatments [1] - The funding will also facilitate expansion into immune diseases [1] Company Focus - Illimis Therapeutics is based in Seoul [1] - The company is focused on developing treatments for Alzheimer's disease [1] - The company is expanding its research focus to include immune diseases [1]

Healthcare & Disease Research - The average onset age of Alzheimer's symptoms for gene mutation carriers in the Richardson family is 39 years old [1] - Three young siblings in the family are hoping to change the course of the disease [1]

Disease Onset & Genetics - The Richardson family's gene mutation carriers show Alzheimer's symptoms at an average age of 39 [1] Research & Hope - Three young siblings in the family are hoping to change the course of Alzheimer's disease [1]

Medical/Genetic Information - The average age of onset for Alzheimer's symptoms in Richardson family members with a specific gene mutation is 39 years old [1] - Three young siblings in the family are hoping to change the course of the disease [1]